MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present ten abstracts at the 2025 American ...

The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date Building ...

Modeling data show Cologuard PlusTM test delivers highest life-years gained with fewest number of colonoscopies among noninvasive colorectal cancer (CRC) screening strategies “Exact Sciences is ...

The nationwide rollout, which Labcorp disclosed Monday, comes weeks after the Centers for Medicare and Medicaid Services approved coverage for ColoSense, and the American Cancer Society named the test ...

Studies show higher completion rates for mt-sDNA testing and the positive impact of patient navigation in expanding access to underserved and older populations “Exact Sciences’ research at ACG 2025 ...

Exact Sciences said the original Cologuard test has been used more than 17 million times since obtaining a nod from the FDA in August 2014. The company plans to launch Cologuard Plus in 2025. (Exact ...

In the past 10 years, the original Cologuard test has been used in more than 19 million cancer screenings—including people taking their second or third test over a period of years. (Exact Sciences) ...

Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from Exact Sciences has a new campaign out that marks the first Spanish-language promotional push for the brand.

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Exact Sciences' claim to fame is Cologuard, an at-home stool-based test it developed for the early detection of colorectal cancer (CRC) in patients with average risk. CRC is the third-most-common ...